

Glenmark receives ANDA approval for Sevelamer Hydrochloride Tablets

11 February 2019 | News

It is a generic version of Renagel Tablets, 400 mg and 800 mg, of Genzyme Corporation



Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration for Sevelamer Hydrochloride Tablets, 400 mg and 800 mg, a generic version of Renagel Tablets, 400 mg and 800 mg, of Genzyme Corporation.

According to IQVIA™ sales data for the 12 month period ending December 2018, the Renagel Tablets, 400 mg and 800 mg market2 achieved annual sales of approximately \$102.1 million.

Glenmark's current portfolio consists of 149 products authorized for distribution in the U.S. marketplace and 53 ANDA's pending approval with the U.S. FDA.